Needham & Company Maintains a 'Buy' on Vertex (VRTX); Adjusting Q2 Lower, But Positive on Cash Flow

July 18, 2012 1:10 PM EDT Send to a Friend
Get Alerts VRTX Hot Sheet
Price: $78.48 +0.06%

Rating Summary:
    17 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 24 | New: 29
Trade VRTX Now!
Needham & Company maintains a 'Buy' on Vertex (NASDAQ: VRTX).

Analyst, Alan Carr, said, "Our 2Q12 Kalydeco and Incivek U.S. sales estimates are $50M (unchanged) and $344M (was $367M), reflecting updated IMS data. The company reported Kalydeco and Incivek sales of $18.0M and 357.0M in 1Q12. Our 2Q12 GAAP EPS estimate is $0.59 (was $0.71)...We believe the stock is attractive given cash flow from Incivek and underappreciated potential for Kalydeco/VX-809 in the F508del patient population."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $52.71 yesterday, with a 52 week range of $26.50-$66.10.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment